在辅助免疫疗法试验中,评估无复发生存率作为整体生存的终点
Yuanfang Li1, Shuqiang Yuan1, Yingbo Chen1
1Department of Gastric Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
Journal of the National Cancer Institute
|June 30, 2023
概括
在辅助免疫疗法试验中,无复发生存率 (RFS) 不是整体生存率 (OS) 的可靠替代品. 这一元分析建议使用OS作为主要终点,以更好地评估治疗疗效.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 无复发生存率 (RFS) 经常被用作早期疾病辅助免疫疗法试验的主要终点.
- 在这种情况下,RFS作为总生存 (OS) 的替代品的有效性仍然不确定.
结论:
- 在辅助免疫疗法试验中,元分析没有发现RFS和OS之间的临床强烈关联.
- 这些发现挑战了RFS作为主要疗效终点的使用.
- 在这种临床背景下,建议将整体存活率 (OS) 作为主要终点.
相关概念视频
Cancer Survival Analysis
397
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
397
Assumptions of Survival Analysis
157
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
157
Comparing the Survival Analysis of Two or More Groups
227
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
227
Kaplan-Meier Approach
190
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
190
Actuarial Approach
98
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
98
Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573


